EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Aroa Biosurgery's enterprise value is A$145.90 Mil.
Aroa Biosurgery's Revenue for the trailing twelve months (TTM) ended in Sep. 2023 was A$62.90 Mil. Therefore, Aroa Biosurgery's EV-to-Revenue for today is 2.32.
The historical rank and industry rank for Aroa Biosurgery's EV-to-Revenue or its related term are showing as below:
ASX:ARX'
s EV-to-Revenue Range Over the Past 10 Years
Min: 2.28 Med: 6.45 Max: 17.23
Current: 2.32
During the past 4 years, the highest EV-to-Revenue of Aroa Biosurgery was 17.23. The lowest was 2.28. And the median was 6.45.
ASX:ARX's EV-to-Revenue is ranked better than 58.67% of 825
companies
in the Medical Devices & Instruments industry
Industry Median: 3.07
vs ASX:ARX: 2.32
As of today (2024-04-25), Aroa Biosurgery's stock price is A$0.50.
Aroa Biosurgery's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2023 was A$0.18. Therefore, Aroa Biosurgery's PS Ratio for today is 2.73.
Aroa Biosurgery EV-to-Revenue Historical Data
The historical data trend for Aroa Biosurgery's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Aroa Biosurgery's EV-to-Revenue
For the Medical Devices subindustry, Aroa Biosurgery's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aroa Biosurgery's EV-to-Revenue Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Aroa Biosurgery's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Aroa Biosurgery's EV-to-Revenue falls into.
Aroa Biosurgery's current Enterprise Value is A$145.90 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Aroa Biosurgery's Revenue for the trailing twelve months (TTM) ended in Sep. 2023 was A$62.90 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aroa Biosurgery's share price for today is A$0.50.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Sep. 2023 was A$0.18.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aroa Biosurgery EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Aroa Biosurgery's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Aroa Biosurgery Ltd is a soft tissue regeneration company which develops, manufactures and sells medical devices for wound and soft tissue repair using its proprietary extracellular matrix (ECM) technology. It is focused on improving the rate and quality of healing in complex wounds and soft tissue reconstruction. The Company is in the business of developing, manufacturing and selling soft tissue repair products. The company's principal market is the United States where it has five key products for sale targeting chronic wounds, hernia, plastics, reconstructive surgery and trauma/limb salvage/tumor surgery.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ASX:ARX has been successfully added to your